Posts tagged Biological License Applications.
Blogs
8 minute read
Two cases decided over the last three months have added California[1] and Massachusetts[2] to the list of minority states that hold brand name manufacturers of drugs (“Brand Manufacturers”) liable under state “failure to warn” laws when sued by patients that exclusively used a generic version of the Brand Manufacturer’s drug. These cases follow the US Supreme Court decision in PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011) (“PLIVA”), which held that generic drug manufacturers cannot be held liable for failure to update the safety label of a drug or biologic in ...
Blog Editors
Recent Updates
- Governing Health AI Development and Adoption: Insights from HHS’s Recently Announced Strategy to Promote AI in Healthcare
- Stranger Things: New FDA Updates Flip Expectations for the Med Tech Industry in 2026 Upside Down
- The DOJ’s Bulk Sensitive Data Rule and Your Obligation to “Know Your Vendor”
- ACCESS Model: CMMI’s New Technology-Enabled Chronic Care Model
- Courts and CMS So Far Agree: States Are Preempted from Acting on MA Plan Marketing